Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus.
| SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus. Nirmatrelvir is the main component of Pfizer’s PAXLOVID™, which was recently authorized to treat COVID-19. PAXLOVID also includes ritonavir, which is an HIV drug.
“We’re pleased to report additional progress on our COVID-19 program,” said Dr. Amit Kumar, President, CEO and Chairman of Anixa Biosciences. “Currently authorized oral antivirals for the treatment of COVID-19 are repurposed compounds originally designed to target other viruses. Anixa’s compounds have been designed specifically to target the enzymes of SARS-CoV-2. In this study, we performed a head-to-head analysis via a Fluorescence Resonance Energy Transfer (FRET) assay that tested the ability of compounds to inhibit the function of Mpro. These in vitro assays were conducted outside of a cellular or living organism context. The results from this head-to-head in vitro analysis suggest that our compound may be more effective than the authorized protease inhibitors. We are now testing the compound in cellular assays as well as animal studies. In addition, the structure of this lead compound indicates that additional modifications could produce even more potent compounds. We are engaged in synthesizing additional compounds for further testing.” Dr. Kumar added, “Anixa’s compounds target the same protease as PAXLOVID, as well as use a similar mechanism of action, so we believe that the effectiveness of PAXLOVID in the clinic provides early proof-of-concept for Anixa’s approach. We look forward to moving these compounds forward and sharing more data in the future.” Since the crystal structure of Mpro of SARS-CoV-2 was published, Anixa has worked in partnership with MolGenie to identify compounds that could inhibit this enzyme. Notably, the program is not reliant on targeting the SARS-CoV-2 spike protein. Recently identified variants, like Delta and Omicron, are characterized by mutations in the spike protein, but Mpro is largely conserved across all of these variants. Therefore, Anixa expects its compounds will be effective against all the currently known variants. Dr. Lutz Weber, President and Chief Executive Officer of MolGenie, added, “We started our research by using artificial intelligence to find compounds that could target Mpro, which we knew would be an important target in the fight against this virus. This head-to-head analysis with nirmatrelvir is an encouraging early sign of the validity of our strategy. It’s clear that more COVID-19 therapies—particularly inexpensive, room temperature-stable, oral therapies with improved pharmaco-dynamic properties—are needed, and we are proud to be part of this important effort.” About MolGenie GmbH About Anixa Biosciences, Inc. Forward-Looking Statements Contacts Company Contact: Media: Investors:
SOURCE Anixa Biosciences, Inc. | ||
Company Codes: NASDAQ-NMS:ANIX |
View original content to download multimedia:
